[Olanzapine-induced diabetes mellitus]

Area of Science:

• Pharmacology
• Endocrinology
• Metabolic Disorders

Background:

• Olanzapine is an atypical antipsychotic medication used for treating schizophrenia and bipolar disorder.
• Metabolic side effects, including hyperglycemia and diabetes mellitus, are recognized risks associated with olanzapine therapy.

Observation:

• Clinical observations indicate a correlation between olanzapine use and the development of hyperglycemia.
• Patients treated with olanzapine exhibit an increased incidence of new-onset diabetes mellitus.

Findings:

• Weight gain is a common side effect of olanzapine, significantly contributing to metabolic disturbances.
• Decreased insulin sensitivity, primarily driven by olanzapine-induced weight gain, is identified as a key mechanism impacting glucose metabolism.
• Olanzapine may interfere with glucose homeostasis through various pathways, with insulin resistance being the most clinically relevant.

Implications:

• This highlights the importance of monitoring glucose levels and weight in patients undergoing olanzapine treatment.
• Understanding the mechanisms of olanzapine-induced hyperglycemia can inform preventative strategies and patient management.
• Further research into mitigating insulin resistance could improve the metabolic safety profile of olanzapine.